口服药物革新免疫学

Revolutionizing Immunologywith Oral Medicines Nello Mainolfi, PhD, Founder, President & CEOKymera Therapeutics J.P. Morgan Healthcare Conference | January 2026 Forward Looking Statements Thispresentationcontainsforward-lookingstatementswithinthemeaningofthePrivateSecuritiesLitigationReformActof1995andotherfederalsecuritieslaws.Thesestatementsinclude,butarenotlimitedto,impliedandexpressstatementsaboutourstrategy,businessplansandobjectivesforourprograms,includingthetherapeuticpotential,clinicalbenefitsandsafetyprofilesofsuchproductcandidates;expectationsregardingtiming,successanddataannouncementsofongoingpreclinicalstudiesandclinicaltrials;thepreliminarycross-studyassessmentscomparingnon-head-to-headclinicaldataofKT-621topublisheddatafordupilumab;ourabilitytoinitiatenewclinicalprograms,theinitiation,timing,progressandresultsofourcurrentandfuturepreclinicalstudiesandclinicaltrialsofourcurrentandprospectiveproductcandidates,ourplanstodevelopandcommercializeourcurrentandanyfutureproductcandidatesandtheimplementationofourbusinessmodelandstrategicplansforourbusiness,current;anyfutureproductcandidates;andourfinancialconditionandexpectedcashrunwayinto2029.Allstatementsotherthanstatementsofhistoricalfactscontainedinthispresentation,includingexpressorimpliedstatementsregardingourstrategy,futurefinancialcondition,futureoperations,projectedcosts,prospects,plans,objectivesofmanagementandexpectedmarketgrowth,areforward-lookingstatements.Insomecases,youcanidentifyforward-lookingstatementsbyterminologysuchas‘‘anticipate,’’“upcoming,”‘‘assume,’’‘‘believe,’’‘‘could,’’‘‘estimate,’’‘‘expect,’’‘‘goal,’’‘‘intend,’’‘‘may,’’“milestones,”‘‘objective,’’‘‘plan,’’‘‘predict,’’‘‘potential,’’‘‘seek,’’‘‘should,’’‘‘target,’’‘‘will,’’‘‘would’’andothersimilarexpressionsthatarepredictionsoforindicatefutureeventsandfuturetrends,orthenegativeofthesetermsorothercomparableterminology.Wemaynotactuallyachievetheplans,intentionsorexpectationsdisclosedinourforward-lookingstatements,andyoushouldnotplaceunduerelianceonourforward-lookingstatements.Youshouldnotrelyuponforward-lookingstatementsaspredictionsoffutureeventsandactualresultsoreventscoulddiffermateriallyfromtheplans,intentionsandexpectationsdisclosedherein. Anyforward-lookingstatementsarebasedonmanagement'scurrentexpectationsandbeliefsandaresubjecttoanumberofrisks,uncertaintiesandimportantfactorsthatmaycauseactualeventsorresultstodiffermateriallyfromthoseexpressedorimpliedbyanyforward-lookingstatementsincluding,withoutlimitation,risksassociatedwith:thetimingandanticipatedresultsofourcurrentandfuturepreclinicalstudiesandclinicaltrials,supplychain,strategyandfutureoperations;thedelayofanycurrentandfuturepreclinicalstudiesorclinicaltrialsorthedevelopmentofourdrugcandidates;theriskthattheresultsofpriorpreclinicalstudiesandclinicaltrialsmaynotbepredictiveoffutureresultsinconnectionwithcurrentorfuturepreclinicalstudiesandclinicaltrials,includingthoseforKT-621,KT-579,KT-485/SAR447971andCDK2degraders;theriskthatcross-trialcomparisonsmaynotbereliableasnohead-to-headtrialshavebeenconductedcomparingKT-621todupilumab,andPhase1clinicaldataforKT-621maynotbedirectlycomparabletodupilumab’sclinicaldataduetodifferencesinmoleculecomposition,trialprotocols,dosingregimens,andpatientpopulationsandcharacteristics;theriskthatourstrategicpartnershipswithSanofiandGileadmaynotbeabletosuccessfullyacceleratethedevelopmentandcommercializationoftheIRAK4andCDK2degraderprogram,respectively;ourabilitytosuccessfullydemonstratethesafetyandefficacyofourdrugcandidates;thetimingandoutcomeofanyinteractionswithregulatoryauthorities;obtaining,maintainingandprotectingourintellectualproperty;ourrelationshipswithexistingandfuturecollaborationpartners;theavailabilityoffundingsufficientfortheCompany’soperatingexpensesandcapitalexpenditurerequirements,theimpactsofcurrentmacroeconomicandgeopoliticalevents.Theserisksanduncertaintiesaredescribedingreaterdetailinthesectionentitled“RiskFactors”intheCompany’smostrecentQuarterlyReportonForm10-QandinsubsequentfilingswiththeSecuritiesandExchangeCommission.Inaddition,anyforward-lookingstatementsrepresentKymera’sviewsonlyasoftodayandshouldnotberelieduponasrepresentingitsviewsasofanysubsequentdate.Kymeraexplicitlydisclaimsanyobligationtoupdateanyforward-lookingstatements,exceptasrequiredbylaw.Norepresentationsorwarranties(expressedorimplied)aremadeabouttheaccuracyofanysuchforward-lookingstatements.Asaresultoftheserisksandothers,includingthosesetforthinourfilingswiththeSEC,actualresultscouldvarysignificantlyfromthoseanticipatedinthispresentation,andourfinancialconditionandresultsofoperationscouldbemateriallyadverselyaffected. Certaininformationcontainedinthispresentationandstatementsmadeorallyduringthispresentationrelatetoorisbasedonstudies,publications,surveysandotherdataobtainedfromthird-partysourcesandtheCompany’sowninternalestimatesandresearch.Nohead-to-headtrialshavebeenconductedcomparingKT-621todupilumab.Phase1clinicaldataforKT-621maynotbedirectlycomparabletodupilumab’sclinicaldataduetodiffere